EXELIXIS INC's ticker is EXEL and the CUSIP is 30161Q104. A total of 365 filers reported holding EXELIXIS INC in Q1 2022. The put-call ratio across all filers is 0.42 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $68,573,933 | +38.7% | 3,138,395 | +21.3% | 0.01% | +40.0% |
| Q2 2023 | $49,443,704 | -0.9% | 2,587,321 | +0.6% | 0.01% | 0.0% |
| Q1 2023 | $49,915,340 | +34.6% | 2,571,630 | +11.2% | 0.01% | +25.0% |
| Q4 2022 | $37,086,360 | +81.6% | 2,312,117 | +77.6% | 0.00% | +33.3% |
| Q3 2022 | $20,418,000 | -38.5% | 1,302,172 | -18.4% | 0.00% | -25.0% |
| Q2 2022 | $33,206,000 | +72.0% | 1,594,953 | +87.3% | 0.00% | +33.3% |
| Q1 2022 | $19,305,000 | +30.1% | 851,635 | +4.9% | 0.00% | +50.0% |
| Q4 2021 | $14,838,000 | -10.3% | 811,675 | +3.7% | 0.00% | 0.0% |
| Q3 2021 | $16,550,000 | +19.2% | 782,886 | +2.7% | 0.00% | 0.0% |
| Q2 2021 | $13,887,000 | +26.1% | 762,122 | +56.3% | 0.00% | 0.0% |
| Q1 2021 | $11,012,000 | -1.9% | 487,470 | -12.8% | 0.00% | 0.0% |
| Q4 2020 | $11,225,000 | +25.0% | 559,254 | +52.3% | 0.00% | 0.0% |
| Q3 2020 | $8,980,000 | -1.8% | 367,313 | -4.7% | 0.00% | 0.0% |
| Q2 2020 | $9,149,000 | -2.3% | 385,439 | -29.1% | 0.00% | -33.3% |
| Q1 2020 | $9,368,000 | -12.3% | 544,014 | -10.3% | 0.00% | +50.0% |
| Q4 2019 | $10,683,000 | +12.2% | 606,337 | +12.6% | 0.00% | -33.3% |
| Q3 2019 | $9,522,000 | -63.8% | 538,421 | -56.3% | 0.00% | -57.1% |
| Q2 2019 | $26,323,000 | -26.2% | 1,231,767 | -17.8% | 0.01% | -30.0% |
| Q1 2019 | $35,664,000 | +53.9% | 1,498,484 | +27.2% | 0.01% | +42.9% |
| Q4 2018 | $23,170,000 | +118.6% | 1,177,915 | +96.9% | 0.01% | +133.3% |
| Q3 2018 | $10,599,000 | -20.5% | 598,105 | -3.4% | 0.00% | -25.0% |
| Q2 2018 | $13,327,000 | -44.5% | 619,296 | -42.8% | 0.00% | -42.9% |
| Q1 2018 | $24,001,000 | -21.8% | 1,083,555 | +7.3% | 0.01% | -12.5% |
| Q4 2017 | $30,707,000 | +50.5% | 1,010,107 | +19.9% | 0.01% | +33.3% |
| Q3 2017 | $20,408,000 | +37.5% | 842,228 | +39.8% | 0.01% | +50.0% |
| Q2 2017 | $14,838,000 | -50.1% | 602,451 | -56.1% | 0.00% | -20.0% |
| Q1 2017 | $29,756,000 | -38.8% | 1,373,180 | -57.9% | 0.01% | -37.5% |
| Q4 2016 | $48,620,000 | +401.5% | 3,260,926 | +330.3% | 0.01% | +166.7% |
| Q3 2016 | $9,694,000 | +212.4% | 757,897 | +90.7% | 0.00% | +200.0% |
| Q2 2016 | $3,103,000 | +137.1% | 397,359 | +21.4% | 0.00% | 0.0% |
| Q1 2016 | $1,309,000 | -30.9% | 327,441 | -2.5% | 0.00% | 0.0% |
| Q4 2015 | $1,893,000 | -39.2% | 335,786 | -39.5% | 0.00% | 0.0% |
| Q3 2015 | $3,115,000 | +336.3% | 555,375 | +192.5% | 0.00% | – |
| Q2 2015 | $714,000 | -37.6% | 189,890 | -57.3% | 0.00% | – |
| Q1 2015 | $1,144,000 | -44.1% | 444,873 | -68.7% | 0.00% | -100.0% |
| Q4 2014 | $2,046,000 | +677.9% | 1,420,933 | +725.3% | 0.00% | – |
| Q3 2014 | $263,000 | -73.3% | 172,163 | -40.8% | 0.00% | – |
| Q2 2014 | $985,000 | -10.5% | 290,712 | -6.6% | 0.00% | – |
| Q1 2014 | $1,101,000 | -14.0% | 311,189 | +49.0% | 0.00% | -100.0% |
| Q4 2013 | $1,280,000 | -13.5% | 208,903 | -17.8% | 0.00% | 0.0% |
| Q3 2013 | $1,479,000 | +48.0% | 253,997 | +15.3% | 0.00% | 0.0% |
| Q2 2013 | $999,000 | – | 220,225 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Meditor Group Ltd | 15,001,073 | $265,294,000 | 64.62% |
| Sargent Investment Group, LLC | 465,620 | $8,234,000 | 3.70% |
| Orbimed Advisors | 3,912,900 | $69,200,000 | 1.31% |
| Bellevue Group AG | 3,858,700 | $68,241,000 | 1.27% |
| TEALWOOD ASSET MANAGEMENT INC | 137,129 | $2,425,000 | 1.04% |
| CAPITAL MANAGEMENT CORP /VA | 200,995 | $3,555,000 | 0.97% |
| Penn Capital Management Company, LLC | 517,988 | $9,161,000 | 0.96% |
| Chicago Capital, LLC | 801,560 | $14,176,000 | 0.95% |
| Portolan Capital Management | 454,444 | $8,037,000 | 0.91% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 103,534 | $1,830,000 | 0.85% |